We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
The Therapeutic Goods Administration (TGA) has issued 2 infringement notices totalling $7,716 to a Queensland-based individual for the alleged unlawful importation of counterfeit botulinum toxin type A and the unlawful advertising of cosmetic injectables in contravention of the Therapeutic Goods Act 1989 (the Act).
It is alleged that the individual unlawfully imported counterfeit botulinum toxin type A products into Australia and advertised prescription-only cosmetic injectables to the public via social media platforms.
Substances used in cosmetic injections, such as botulinum toxin type A, are generally regulated as Schedule 4 medicines. In Australia, these products can only be lawfully imported with a valid prescription or written authority.
The Act prohibits the importation of counterfeit therapeutic goods into Australia and the advertising of prescription medicines, including prescription-only cosmetic injectable treatments, to the public.
Consumers considering treatment with cosmetic injectables should be aware of the risks associated with unapproved therapeutic goods, which may be counterfeit and pose serious health risks. The TGA has recently published a safety alert regarding counterfeit botulinum toxin products detected at the Australian border.
The TGA will continue to take action where serious non-compliance with the Act is identified in accordance with our regulatory compliance framework. This may include issuing infringement notices, directions and prevention notices, or civil or criminal proceedings.
If you suspect non-compliance in relation to therapeutic goods, or their advertising, you can report it to the TGA at any time.
Contact for members of the media:
- Email: news@health.gov.au
- Phone: 02 6289 7400
